[{"id":"1ba66b3e-54fe-4d02-972d-169ab5065f83","acronym":"","url":"https://clinicaltrials.gov/study/NCT05435274","created_at":"2022-06-28T15:54:10.303Z","updated_at":"2024-07-02T16:36:08.178Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05435274","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 mutation • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR exon 20 mutation • HER-2 exon 23 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HS-10376"],"overall_status":"Recruiting","enrollment":" Enrollment 380","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 10/07/2024","primary_completion_date":" 10/07/2024","study_txt":" Completion: 10/07/2025","study_completion_date":" 10/07/2025","last_update_posted":"2022-06-28"}]